Ken Griffin Ocuphire Pharma, Inc. Transaction History
Citadel Advisors LLC
- $509 Billion
- Q1 2025
A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Ocuphire Pharma, Inc. stock. As of the latest transaction made, Citadel Advisors LLC holds 13,700 shares of OCUP stock, worth $13,426. This represents 0.0% of its overall portfolio holdings.
Number of Shares
13,700
Previous 12,600
8.73%
Holding current value
$13,426
Previous $12,000
8.33%
% of portfolio
0.0%
Previous 0.0%
Shares
8 transactions
Others Institutions Holding OCUP
# of Institutions
50Shares Held
17.7MCall Options Held
13.7KPut Options Held
1K-
Perceptive Advisors LLC New York, NY4.33MShares$4.24 Million0.18% of portfolio
-
Bios Capital Management, LP Fort Worth, TX3.68MShares$3.61 Million4.77% of portfolio
-
Nantahala Capital Management, LLC New Canaan, CT3.16MShares$3.09 Million0.14% of portfolio
-
Opaleye Management Inc. Boston, MA1.18MShares$1.15 Million0.32% of portfolio
-
Vanguard Group Inc Valley Forge, PA992KShares$972,3560.0% of portfolio
About Ocuphire Pharma, Inc.
- Ticker OCUP
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 20,579,800
- Market Cap $20.2M
- Description
- Ocuphire Pharma, Inc., a clinical-stage ophthalmic biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of refractive and retinal eye disorders. Its lead product candidate is Nyxol eye drops, a once-daily preservative-free eye drop formulation of phentolamine mesylate, which is in Phase III clinical tr...